Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 15/20 | 0.51 |
| ▸ | MMP1 | P03956 | 11/20 | 0.51 |
| ▸ | MMP9 | P14780 | 7/20 | 0.51 |
| ▸ | MMP8 | P22894 | 8/20 | 0.49 |
| ▸ | MMP3 | P08254 | 6/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.45 |
| ▸ | MMP7 | P09237 | 7/20 | 0.43 |
| ▸ | MMP12 | P39900 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7255486 | 0.80 | MMP8 (0.46) | MMP13MMP1MMP9MMP8MMP3 | |
| Hydroxyamine SCHEMBL5894189 | 0.76 | FKBP1A (0.40) | MMP13MMP1MMP9MMP8MMP3 | |
| SCHEMBL6669900 | 0.75 | MMP3 (0.51) | MMP13MMP1MMP9MMP8MMP3 | |
| SCHEMBL6667010 | 0.75 | MMP3 (0.51) | MMP13MMP1MMP9MMP8MMP3 | |
| SCHEMBL3256303 | 0.72 | FKBP1A (0.56) | MMP13MMP1MMP8MMP3FKBP1A | |
| SCHEMBL3256301 | 0.72 | FKBP1A (0.56) | MMP13MMP1MMP8MMP3FKBP1A | |
| SCHEMBL6830973 | 0.71 | FKBP1A (0.58) | MMP13MMP1MMP8MMP3FKBP1A | |
| SCHEMBL4959930 | 0.71 | FKBP1A (0.52) | MMP13MMP1MMP8MMP3FKBP1A | |
| SCHEMBL6830972 | 0.71 | FKBP1A (0.58) | MMP13MMP1MMP8MMP3FKBP1A | |
| SCHEMBL4959935 | 0.71 | FKBP1A (0.52) | MMP13MMP1MMP8MMP3FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147095-B1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6544984-B1 | Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. | AMERICAN CYANAMID COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1147095-A1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044730-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |